Brief: Lundbeck Announces Positive Phase II Proof Of Concept Results With Lu Ag09222 In Migraine Prevention
April 19 (Reuters) - H Lundbeck A/S HLUNb.CO :
* ANNOUNCES POSITIVE PHASE II PROOF OF CONCEPT RESULTS WITH LU AG09222 IN MIGRAINE
PREVENTION
* HOPE TRIAL MET ITS PRIMARY ENDPOINT IN MIGRAINE PREVENTION
* PATIENTS TREATED WITH LU AG09222 HAD STATISTICALLY SIGNIFICANTLY GREATER REDUCTION IN
NUMBER OF
MONTHLY MIGRAINE DAYS FROM BASELINE TO WEEKS 1 TO 4 OF TREATMENT VERSUS PLACEBO
* FULL TRIAL RESULTS ARE NOT YET AVAILABLE
* LU AG09222 WAS GENERALLY WELL TOLERATED
Source text for Eikon: ID:nWkr53nndX
Further company coverage: HLUNb.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options